← Back to Search

Small Molecule

Cedirogant for Psoriasis

Phase 2
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 16
Awards & highlights

Study Summary

This trial will assess the safety and effectiveness of cedirogant compared to placebo in adults with moderate to severe plaque psoriasis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving 75% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 75) at Week 16
Secondary outcome measures
Percentage of Participants Achieving 100% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 100) at Week 16
Percentage of Participants Achieving 50% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 50) at Week 16
Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) at Week 16
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 75 mg CedirogantExperimental Treatment1 Intervention
Participants received 75 mg cedirogant orally once daily (QD) for 16 weeks.
Group II: 150 mg CedirogantExperimental Treatment1 Intervention
Participants received 150 mg cedirogant orally once daily (QD) for 16 weeks.
Group III: 375 mg CedirogantPlacebo Group1 Intervention
Participants received 375 mg cedirogant orally once daily (QD) for 16 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Participants received placebo capsules for cedirogant orally once daily (QD) for 16 weeks.

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
946 Previous Clinical Trials
496,316 Total Patients Enrolled
61 Trials studying Psoriasis
125,120 Patients Enrolled for Psoriasis
ABBVIE INC.Study DirectorAbbVie
387 Previous Clinical Trials
140,997 Total Patients Enrolled
21 Trials studying Psoriasis
17,571 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Cedirogant been given the stamp of approval by the FDA?

"Cedirogant's safety is rated as a 2, given that only preliminary data exists in regards to its efficacy and there are some findings which support it being safe."

Answered by AI

Are there any vacancies available for those wishing to participate in this clinical trial?

"As confirmed by clinicaltrials.gov, the recruitment phase of this specific medical trial has now concluded; it was originally posted on November 16th 2021 and last updated on November 11th 2022. However, there are still 167 other trials that remain open to enrollment at present."

Answered by AI

What are the criteria for enrollment in this clinical trial?

"This trial is looking for 200 individuals aged between 18 and 65 who have been living with psoriasis for a minimum of 6 months. To qualify, applicants must meet the following prerequisites: - Patients diagnosed with moderate-to-severe plaque psoriasis that requires systemic or phototherapy treatment."

Answered by AI

How many medical facilities have been enlisted to conduct this experiment?

"Currently, this medical trial is enrolling patients from thirteen distinct sites. These are scattered across the US and Canada, including Atlanta, Calgary and Spokane amongst other locales. It's important to choose a nearby clinic for convenience should you join the study."

Answered by AI

Is this experiment available to elderly individuals?

"The eligibility requirements stipulate that the minimum age of enrolment must be 18 and no more than 65 years old."

Answered by AI

Who else is applying?

What state do they live in?
Florida
What portion of applicants met pre-screening criteria?
Met criteria
~47 spots leftby Mar 2025